Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01504)
Name
Trifarotene
Synonyms    Click to Show/Hide the Synonyms of This API
Trifarotene; 895542-09-3; UNII-0J8RN2W0HK; CD5789; 0J8RN2W0HK; CD-5789; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; 3''-(tert-butyl)-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)-[1,1':3',1''-terphenyl]-4-carboxylic acid; Trifarotene [USAN:INN]; Aklief; Aklief (TN); CD 5789; Trifarotene (USAN/INN); SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; BCP31392; EX-A2704; BDBM50457548; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; BS-17812; HY-100256; CS-0018407; D11225; CD5789; CD-5789; CD 5789; Q27236856; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
Clinical Status
Approved
PubChem CID
11518241
Formula
C29H33NO4
Canonical SMILES
CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
InChI
1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
InChIKey
MFBCDACCJCDGBA-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11518241"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 459.6 Topological Polar Surface Area 70
XlogP 6.3 Complexity 647
Heavy Atom Count 34 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Trifarotene 0.005% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Allantoin; Copolymer Of Acrylamide And Sodium Acryloyldimethyltaurate; Dispersion 40% In Isohexadecane; Cyclomethicone; 5% Ethanol; Medium-Chain Triglycerides; Phenoxyethanol; Propylene Glycol; Purified Water
                   Dosage Form Cream
                   Company Galderma Laboratories
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [1]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [2]
References
1 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
2 Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm. 2013 Apr 15;447(1-2):192-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.